The appointment reflects the company’s strategic growth and the expansion of its life sciencesfund strategies
Paris – February 12th, 2020 — Sofinnova Partners, a leading European life sciences venture capital firmbased in Paris, London, and Milan, announced today that it has appointed Robert Carroll as Partner, Headof Investor Relations. He will lead the firm’s fundraising and investor relations team and brings a dedicatedfocus to supporting and growing Sofinnova Partners’ investor base.
Dr. Carroll has a decade of experience working with institutional investors and raising capital foralternative assets. Prior to joining Sofinnova Partners, he helped establish and co-lead PwC’s GlobalFundraising Advisory Platform. Previously, Dr. Carroll worked at Mercury Capital Advisors, a global privatefundraising and investment advisory firm, where he supported the needs of institutional investors andsuccessfully raised capital across the alternative asset spectrum.
Prior to his career in private placement, Dr. Carroll, who holds a Ph.D. in Chemistry from University CollegeLondon, worked as a principal scientist and project lead at Pfizer, developing pharmaceutical assets fromdiscovery to pre-clinical and into clinical trials. He also held positions at GlaxoSmithKline and Eli Lilly.
“We are thrilled to have Rob on board, and to be able to bring his deep scientific and financial experienceto the helm of our investor relations,” said Antoine Papiernik, Managing Partner and Chairman of the firm.
“Rob’s hire reflects the firm’s broader expansion and thoughtful, strategic growth,” he added. Mr.Papiernik said the company has more than €2 billion under management and that €1 billion has beenraised in the last four years, while its team has continued to grow steadily.
Dr. Carroll said “Sofinnova Partners continues to be a pioneer across the life sciences value chain with therecent addition of several new fund strategies, from acceleration to later-stage, and dedicated vehicles forgene and cell therapies, as well as industrial biotechnology. My priority will be to communicate the valueour strategies can bring to the portfolios of our investors.”
Dr. Carroll completed his post-doctoral research at Brock University in Canada, with a focus on the semisynthesisof morphine and its analogues. This work was carried out in collaboration with Noramco (thena part of Johnson & Johnson) and is the subject of a number of patents.
+1 212 223 0561
+33 (0) 6 03 35 92 05